Here are some of our most-listened-to 2020 "Not So Different" podcasts.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are some of our most-listened-to 2020 "Not So Different" podcasts.
Anurag Rathore, PhD, coordinator of the Center of Excellence for Biopharmaceutical Technology in Delhi, India, discusses findings from his study on biosimilar application failures.
Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare in Atlanta, Georgia, explains how a series of steps helped to increase biosimilar utilization within the Emory system and how these initiatives could be implemented on a larger scale.
Ha Kung Wong, an intellectual property law attorney and partner at Venable Fitzpatrick in New York, New York, and April Breyer Menon, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago, Illinois, discuss potential bills to improve biosimilar uptake and their chances for passage.
Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the Association for Accessible Medicines (AAM) in Washington, DC, discusses some of the advocacy changes the organization is looking to advance and their chances of approval.
Lastly, we spoke with Adrian van den Hoven, director general of Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, about their scorecard report for biosimilar access and what European markets they feel need the most work.
To read all these articles and more, visit centerforbiosimilars.com.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.